First-of-Its-Kind Testing Device Allows For Rapid Detection of Bacteria That Identify Risk for Preterm Birth
By LabMedica International staff writers Posted on 14 Oct 2021 |

A newly-developed cost-effective device can rapidly and accurately detect changes in vaginal bacteria and corresponding immune responses in pregnant women, which are associated with increased risk of preterm birth.
The first-of-its-kind testing device developed by researchers at the March of Dimes Prematurity Research Center at Imperial College London (London, UK) may help advance diagnosis and treatment of preterm birth by facilitating faster clinical decision-making and helping improve targeted treatment strategies during pregnancy.
Preterm birth remains a major cause of death worldwide in children under age five. One of the many factors that contribute to a woman's risk of preterm birth is changes during pregnancy to the type and amounts of microbes in the lower reproductive tract, referred to as the vaginal microbiome. In some women, certain bacteria from the microbiome can cause inflammation leading to an increased risk of preterm birth. The new testing device called direct-on-swab metabolic profiling by Desorption Electrospray Ionization Mass Spectrometry (DESI-MS), rapidly analyzes chemicals in a clinical swab to simultaneously determine the type of bacteria in the vagina, and corresponding immune or inflammatory response to the bacteria.
The two-minute test was found to be just as effective as 'gold standard' chemical profiling tests (e.g. Liquid Chromatography-Mass Spectrometry assays) that require detailed sample preparation and extraction making them more time consuming (up to eight hours per assay), costly and difficult to introduce into routine bedside testing. The ability to monitor the vaginal microbiome and inflammation throughout pregnancy with DESI-MS could help identify women at risk of preterm birth sooner, potentially allowing obstetricians to monitor these women more closely and start preventative treatments earlier and in a more targeted way than currently possible.
The researchers tested the direct-on-swab DESI-MS device by analyzing more than 1,000 samples collected from two independent groups of pregnant women (about 400 women in total) in the UK. The data found that women who had changing and diverse vaginal microbiomes (those that contained many different bacteria or had bacteria that changed during pregnancy) had higher rates of preterm birth and were more likely to have increased inflammation. The test also detected inflammation caused by some treatments received during pregnancy (e.g. a stitch put into the cervix for 'cervical cerclage' treatment). This inflammation was most frequently observed in women subsequently experiencing preterm birth.
The device may have broader application to other areas of women's health where the vaginal microbiome has been implicated, including bacterial vaginosis, HIV and HPV infection, cervical dysplasia, IVF failure and miscarriage. The researchers now plan to register the technology and seek regulatory approval for its use in the UK and Europe and, eventually, in North America. They also are planning development of a miniature version of the test that can be used more widely in clinics and would allow for bedside testing.
"We've known for some time that the vaginal microbiome can contribute to the risk of preterm birth, but now we have developed a device which in just a few minutes can report both the microbiome composition and inflammatory status of a sample collected during pregnancy," said Dr. David MacIntyre, Reader in Reproductive Systems Medicine, Institute of Reproductive and Developmental Biology Department of Metabolism, Digestion and Reproduction at Imperial College London. "This is the first rapid testing device of its kind and could be readily transferred to use in a clinical setting. This information could be used by doctors and patients to monitor risk of preterm birth but also to help optimize treatments, such as more selective use of antibiotics."
Related Links:
Imperial College London
Latest Pathology News
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
- Advances in Monkeypox Virus Diagnostics to Improve Management of Future Outbreaks
- Nanoneedle-Studded Patch Could Eliminate Painful and Invasive Biopsies
- AI Cancer Classification Tool to Drive Targeted Treatments
- AI-Powered Imaging Enables Faster Lung Disease Treatment
- New Laboratory Method Speeds Diagnosis of Rare Genetic Disease
- New Technology Autonomously Detects AI Hallucinations in Digital Pathology
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more
AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases
The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. These gut bacteria produce a variety of metabolites... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more